---
title: "United Laboratories Sets Out Board and Committee Structure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286552375.md"
description: "United Laboratories International Holdings has announced its board and committee structure, detailing the composition of its board of directors and key leadership roles. The company emphasizes independent oversight with several independent non-executive directors in multiple committee positions. The latest analyst rating for its stock (HK:3933) is a Buy with a price target of HK$20.00."
datetime: "2026-05-15T10:53:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286552375.md)
  - [en](https://longbridge.com/en/news/286552375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286552375.md)
---

# United Laboratories Sets Out Board and Committee Structure

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The United Laboratories International Holdings ( (HK:3933) ) has provided an update.

The United Laboratories International Holdings Limited has outlined the composition of its board of directors, naming its executive and independent non-executive members and confirming key leadership roles such as chairman and vice-chairman. The company also detailed the membership of its five board committees—Audit, Remuneration, Nomination, Risk Management, and Sustainability—clarifying oversight responsibilities that are important for corporate governance and risk control.

Several independent non-executive directors, including Chong Peng Oon, Prof. Song Ming, and Dr. Fu Qiushi, hold multiple committee positions, underscoring the emphasis on independent oversight in financial reporting, remuneration, and risk management. The inclusion of executive directors on the Nomination, Risk Management, and Sustainability Committees further integrates management and board-level supervision, which may enhance accountability and align strategic, risk, and sustainability priorities for shareholders and other stakeholders.

The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

**More about The United Laboratories International Holdings**

The United Laboratories International Holdings Limited is a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong. It operates in the drug manufacturing sector, with a governance structure that includes executive directors and independent non-executive directors overseeing its strategic and regulatory responsibilities.

**Average Trading Volume:** 9,804,960

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$18.7B

Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03933.HK](https://longbridge.com/en/quote/03933.HK.md)

## Related News & Research

- [United Laboratories Wins Green Light for Trial of Once-Weekly Insulin UBT38006](https://longbridge.com/en/news/285527106.md)
- [Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval](https://longbridge.com/en/news/285448082.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [When Can We Expect A Profit From Island Pharmaceuticals Limited (ASX:ILA)?](https://longbridge.com/en/news/286861950.md)
- [12:49 ETJulia B. Fee Sotheby's International Realty Names Katie Brunner Brokerage Manager of Bedford, N.Y., Office](https://longbridge.com/en/news/286946780.md)